LTRN — Lantern Pharma Share News
0.000.00%
Last trade - 00:00Brief: Lantern Pharma Reports First Quarter 2023 Financial Results
Lantern Pharma Inc expected to post a loss of 48 cents a share - Earnings Preview
Lantern Pharma Inc expected to post a loss of 48 cents a share - Earnings Preview
Brief: Lantern Pharma Receives Notice Of Allowance For Composition Of Matter Patent Covering Drug Candidate Lp-284
Brief: Lantern Pharma Announces First Patient Dosed In Phase 2 Study, Harmonic, For Lp-300 In Never Smokers With Advanced Non-Small Cell Lung Cancer
Lantern Pharma Inc reports results for the quarter ended in December - Earnings Summary
Brief: Lantern Pharma Reports Fourth Quarter And Fiscal Year 2022 Financial Results And Operational Highlights
Lantern Pharma Inc expected to post a loss of 47 cents a share - Earnings Preview
Brief: Lantern Pharma Confirms No Exposure To Silicon Valley Bank, Silvergate Bank, Or Signature Bank
Brief: Lantern Pharma Announces New Data And Development Focus For Lp-100 With Parp Inhibitors
Brief: Lantern Pharma Announces Formation Of Starlight Therapeutics To Advance Transformative Therapies For Central Nervous System and Brain Cancers
Lantern Pharma Inc expected to post a loss of 47 cents a share - Earnings Preview
Brief: Lantern Pharma Expands Clinical Leadership Team To Further Advance Its Ongoing And Upcoming Clinical Trials
Brief: Lantern Pharma And Ttc Oncology Establish Ai Collaboration To Expand The Clinical Development Of Drug Candidate Ttc-352
Brief: Lantern Pharma Inc. - Announced Expansions And Updates To RADR's Product Roadmap
U.S. STOCKS ON THE MOVE-Chord Energy, Kroger, PetMed Express
U.S. STOCKS ON THE MOVE-DoorDash, Walt Disney, Tesla
Brief: Lantern Pharma Receives Pre-IND Feedback From FDA, Clearing Path For Drug Candidate LP-184’s Phase 1 Clinical Trial in Q2 2023
U.S. STOCKS ON THE MOVE-Papa John's, Whirlpool, Coca-Cola